🚨 #ESMO26 | CLARITY-Gastric01 Phase III

Sonesitatug vedotin in CLDN18.2+ gastric/GEJ cancer:

✅ 3L+ OS: 10 vs 5 mo (HR 0.47)
✅ ITT OS: 10.6 vs 6.4 mo
✅ ORR: 23.3% vs 13.8%
⚠️ ITT PFS not significant (p=0.053)

🎯 Promising new ADC in gastric cancer!

#GastricCancer #ADC